AVENTIS PHARMA LIMITED

1. AVENTIS PHARMA LIMITED 1999-12-16 → present
2. MARION MERRELL LIMITED 1995-09-14 → 1999-12-16
3. MARION MERRELL DOW LIMITED 1992-01-06 → 1995-09-14
4. MERRELL DOW PHARMACEUTICALS LIMITED 1983-12-06 → 1992-01-06
5. MERRELL PHARMACEUTICALS LIMITED 1980-12-18 → 1983-12-06

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Forvis Mazars LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the continuing operations and profitability, the directors have no reason to believe that a material uncertainty exists about the ability of the company to ensure that it can meet its liabilities to third parties as they fall due and continue as a going concern for the period to 31 December 2026.”

Group structure

1. AVENTIS PHARMA LIMITED · parent
   1. Genzyme Therapeutics Limited 100% · UK
   2. May & Baker Limited 100% · UK
   3. Fisons Limited 100% · UK
   4. Rhone-Poulenc Rorer Limited 100% · UK

Significant events

• “During the year Sanofi entered into a pension buy-in arrangement covering approximately 95% of the uninsured liabilities under the Sanofi Pension Scheme. This transaction involved the purchase of a bulk annuity policy from a regulated insurance provider, which matches the liabilities of the covered members and is held as a scheme asset. The buy-in does not transfer legal responsibility for the liabilities but provides a contractual right to future payments that mirror the pension obligations. Subsequent to the year-end, in January 2025, Sanofi completed a second bulk annuity transaction covering the remaining 5% of uninsured liabilities for £83.6m. This transaction effectively insures the entirety of the scheme's previously uninsured liabilities. These transactions represent significant risk mitigation steps and are expected to enhance the security of member benefits.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

12

last 12 months

Capital events

2

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +7.7%

  £384,877,000 → £414,634,000

• Cash

  -9%

  £144,000 → £131,000

• Net assets

  -7.2%

  £1,524,758,000 → £1,415,444,000

• Employees

  -12.2%

  666 → 585

• Operating profit

  -141.9%

  £17,893,000 → -£7,498,000

• Profit before tax

  +6.5%

  £71,861,000 → £76,557,000

• Wages

  +1.2%

  £70,110,000 → £70,966,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers